Reducing Time to Discharge after Chemotherapy by Standardizing Workflow and Providing Outpatient Intravenous Hydration.

INTRODUCTION: Patients receiving cyclophosphamide or ifosfamide chemotherapy require intravenous fluid hydration to prevent hemorrhagic cystitis. In selected patients without medical contraindications (ie, excess nausea/vomiting), this hydration may be completed after discharge. We aimed to reduce the time to discharge after completing mesna in patients receiving cyclophosphamide or ifosfamide therapy on an inpatient chemotherapy service. METHODS: The quality improvement team performed a medical record review to capture the time to discharge after mesna therapy and the readmission rate and used quality improvement methods to redesign discharge workflow and increase patient involvement with the discharge process. RESULTS: From August 2017 through July 2018, there were 160 admission encounters (73 patients) for cyclophosphamide or ifosfamide on a dedicated chemotherapy service. Of those encounters, 89 (55.6%) were appropriate for outpatient hydration; 48 (53.9%) of these encounters involved a patient who elected to receive outpatient hydration. Although the median time to discharge for the whole cohort did not change, in encounters where patients chose intravenous outpatient hydration, the median time to discharge was reduced from 2.82 to 0.66 hours (76.6% reduction) after implementing the new discharge workflow. No patients experienced readmission within 48 hours. CONCLUSIONS: Discharge workflow redesign and standardization reduced the time to discharge after chemotherapy in patients who chose outpatient hydration. Outpatient intravenous hydration after cyclophosphamide or ifosfamide appears safe and feasible in selected patient populations.

Simultaneous Adrenocortical Carcinoma and Neuroblastoma in an Infant With a Novel Germline p53 Mutation.

We present an infant with 2 simultaneous, but histologically distinct tumors with a novel germline p53 mutation. The child was found to have a paraspinal neuroblastoma, a concurrent adrenal cortical carcinoma, and an I162F p53 gene mutation. We review the associations of germline p53 mutations (or Li-Fraumeni syndrome) with both tumor types and the current research in similar germline p53 mutations. Finally, we discuss the multiple ways in which our patient is unique including the paucity of cases with simultaneous but histologically unrelated tumors and the fact that our patient is the first reported case of an I162F germline p53 mutation.

Is intensive monitoring during the first transfusion in pediatric patients necessary?

BACKGROUND: Some pediatric patients, typically those that are very young or felt to be especially sick are temporarily admitted to the intensive care unit (ICU) for observation during their first transfusion. If a significant reaction that requires ICU management does not occur, these patients are then transferred to a regular ward where future blood products are administered. The aim of this project was to determine if heightened observation such as temporary ICU admissions for the first transfusion are warranted. METHODS: From the blood bank records of a tertiary care pediatric hospital, a list of patients on whom a transfusion reaction was reported between 2007 and 2012, the type of reaction and the patient's transfusion history, were extracted. The hospital location where the transfusion occurred, and whether the patient was evaluated by the ICU team or transferred to the ICU for management of the reaction was determined from the patient's electronic medical record. RESULTS: There were 174 acute reactions in 150 patients. Of these 150 patients, 13 (8.7%) different patients experienced a reaction during their first transfusion; all 13 patients experienced clinically mild reactions (8 febrile non-hemolytic, 4 mild allergic, and 1 patient who simultaneously had a mild allergic and a febrile non-hemolytic), and none required ICU management. Six severe reactions (6 of 174, 3.4%) involving significant hypotension and/or hypoxia that required acute and intensive management occurred during subsequent (i.e. not the first) transfusion in six patients. CONCLUSIONS: The practice of intensive observation for the first transfusion in pediatric patients is probably unnecessary.